Wolfe Research downgraded shares of NeuroPace (NASDAQ:NPCE – Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Monday,Zacks reports.
NPCE has been the subject of several other reports. JPMorgan Chase & Co. lowered shares of NeuroPace from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $20.00 to $9.00 in a research report on Friday. Leerink Partners cut shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price target on the stock. in a report on Friday. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Cantor Fitzgerald reduced their price objective on shares of NeuroPace from $21.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday. Finally, KeyCorp decreased their target price on shares of NeuroPace from $18.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, NeuroPace currently has an average rating of “Hold” and an average price target of $13.11.
View Our Latest Research Report on NeuroPace
NeuroPace Price Performance
Institutional Investors Weigh In On NeuroPace
Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new position in shares of NeuroPace during the second quarter valued at about $41,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in NeuroPace in the 2nd quarter worth approximately $157,000. Entropy Technologies LP purchased a new stake in NeuroPace during the 3rd quarter worth approximately $146,000. Diversified Trust Co purchased a new stake in NeuroPace during the 3rd quarter worth approximately $153,000. Finally, Bank of America Corp DE purchased a new stake in NeuroPace during the 2nd quarter worth approximately $322,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
NeuroPace News Roundup
Investors following NPCE have been watching these news items:
- Neutral Sentiment: HC Wainwright lowered its price target from $20 to $12 but kept a Buy rating; Cantor Fitzgerald cut its target from $21 to $12 while maintaining Overweight. Both targets remain above the recently cited $7.97 share price, though the sizable reductions temper that potential upside. HC Wainwright ratings Cantor Fitzgerald ratings
- Negative Sentiment: Wolfe Research downgraded NeuroPace from Strong Buy to Hold. Wall Street Zen cut its rating to Sell, while JPMorgan moved to Neutral and Leerink Partners to Market Perform, signaling weaker analyst conviction. Wolfe Research ratings Wall Street Zen downgrade JPMorgan rating change Leerink Partners rating change
- Negative Sentiment: Coverage also highlighted a third-quarter miss and reduced analyst estimates of the company’s fair value, reinforcing concerns about performance and the outlook. Fair value and Q3 miss article
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
See Also
- Five stocks we like better than NeuroPace
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
